The Eleven Fund

The Eleven Fund is a growth equity firm established in 2017, located in Denver, Colorado. The firm specializes in late-stage pre-IPO investments, focusing on sectors such as technology, life sciences, and consumer markets. By targeting companies poised for significant growth, The Eleven Fund aims to provide capital to businesses that are approaching their public offerings, helping them to scale and succeed in competitive environments.

Hart Wasko

Founder and Managing Partner

3 past transactions

Escient Pharmaceuticals

Series C in 2022
Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Alleaves

Series A in 2022
Alleaves is a cannabis technology company that specializes in the cultivation, manufacturing, and sale of cannabis products. The company employs advanced technology solutions to enhance its operations, including AI-based automated dispatch, real-time fleet tracking, and analytics to optimize product delivery. In addition to its cultivation and sales activities, Alleaves offers a comprehensive software platform that enables cannabis cultivators to effectively manage their supply chain, streamline processing, and ensure compliance with regulatory requirements. This platform provides essential tools for tracking and controlling operations from seed to sale, positioning Alleaves as a key player in the cannabis industry. The company maintains contact options via mail and at its physical address.

Pear Therapeutics

Post in 2021
Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.